News | July 05, 2023
Syngene to acquire multi-modal facility from Stelis Biopharma
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The VITA-FAST tokens have been met with overwhelming interest
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
Subscribe To Our Newsletter & Stay Updated
